Insulin Cost Cap Gets Another Look in Congress

“A Senate plan to limit insulin costs in private insurance markets is getting new life after a key committee gave it bipartisan backing,” Axios reports.

“Capping out-of-pocket insulin costs at $35 per month for patients with diabetes in commercial insurance has been a goal for years, but efforts have stalled over concerns about excessive government meddling.”